Quarterly ResultAug 5, 2026, 05:18 PM
Coherus Q2 Net Loss $(20.6)M; LOQTORZI Revenue Up 40%
AI Summary
Coherus Oncology reported a net loss of $(20.6) million for Q2 2026, a significant decline from a net income of $297.8 million in Q2 2025, primarily due to reduced income from discontinued operations. Net revenue from continuing operations, driven by LOQTORZI sales, increased to $14.3 million. The company maintains $105.3 million in cash and marketable securities but anticipates needing additional funding for clinical trials and commercialization.
Key Highlights
- Q2 2026 net loss was $(20.6) million, compared to net income of $297.8 million in Q2 2025.
- Q2 2026 net revenue from continuing operations increased to $14.3 million.
- LOQTORZI net product revenue grew to $13.6 million in Q2 2026 from $10.0 million.
- Q2 2026 net loss per share was $(0.13), down from $2.57 in Q2 2025.
- Cash, cash equivalents, and marketable securities totaled $105.3 million as of June 30, 2026.
- Net cash used in operating activities was $(119.9) million for the six months ended June 30, 2026.
- Accumulated deficit reached $(1.44) billion as of June 30, 2026.
- Raised $53.7 million from common stock public offering in the first half of 2026.
Price Impact
More from CHRS